Ovid Therapeutics Inc. OVID 深 滬
已收盤 10-24 16:00:00 美东时间
1.63
+0.070
+4.49%
華盛通- 最 高1.65
- 今 開1.56
- 成交量 142.97万股
- 最 低 1.56
- 昨 收 1.56
- 總市值 1.16亿
- 52周最高 2.01
- 市盈率 靜 --
- 換手率 2.01%
- 52周最低 0.2425
- 委 比 -38.79%
- 總股本 7110.95万
- 歷史最高 15.89
- 量 比 0.99
- 振 幅 5.77%
- 歷史最低 0.2425
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NUTEX HEALTH PROVIDES CORPORATE UPDATE
Significant Year-over-Year Growth in Patient Volume and Cash Collections HOUSTON, Oct. 20, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physicia...
10-20 17:30
GALIANO GOLD PROVIDES NOTICE OF THIRD QUARTER 2025 RESULTS
VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ - Galiano Gold Inc. ("Galiano" or the "Company") (TSX: GAU) (NYSE American: GAU) is pleased to announce it will release its third quarter ("Q3") 2025...
10-08 20:30
Ovid Therapeutics jumps 28% on $175M private placement
Ovid Therapeutics (NASDAQ:OVID) entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of up to $175M, includin...
10-03 19:22
Ovid Therapeutics Reports Results for New Epilepsy Drug in Early Human Trial
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase
10-03 19:03
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Ovid Therapeutics has secured up to $175 million through a PIPE financing, with an initial close of $81 million and potential for additional $94 million via warrant exercises. The funding will support operations, R&D, and clinical pipeline through 2028. Invest participation includes notable firms like Janus Henderson Investors and RA Capital Management. The financing includes Series B Preferred Stock and warrants for common stock issuance, with w...
10-03 11:05
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
Ovid Therapeutics announced positive results from its Phase 1 study of OV329, a next-generation GABA-AT inhibitor for drug-resistant epilepsies. The study showed OV329 achieved significant inhibition of GABA-AT across multiple metrics, comparable or superior to vigabatrin, with a favorable safety and tolerability profile. OV329 demonstrated increased GABA levels and significant inhibition via TMS biomarkers. The company plans to advance OV329 int...
10-03 11:00
Is The Nike Turnaround Story In Play?
Nike delivers a mixed but encouraging quarter, and a turnaround narrative is starting to take shape.
10-02 00:11
CONTANGO PROVIDES UPDATE ON FINANACING AND EXPLORATION PLANS
FAIRBANKS, Alaska, Sept. 26, 2025 /PRNewswire/ - Contango ORE, Inc. ("Contango" or the "Company") (NYSE American: CTGO), announces that it will hold a webinar on Friday, September 26, 2025 a...
09-26 22:07
Sanofi And Novavax Issue Statement On Nuvaxovid COVID-19 Vaccine For ACIP
https://ir.novavax.com/press-releases/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP Introductory Remarks for Nuvaxovid at September 2025 Advisory Committee on Immunization Practices
09-20 00:10
